AstraZeneca, Daiichi's Enhertu gets NICE recommendation for HER2-low metastatic breast cancer

NICE has recommended AstraZeneca and Daiichi Sankyo's Enhertu for HER2-low metastatic breast cancer, clearing the way for NHS access in England for women with the aggressive form of the disease.

Detected & updated continuously · Source: Nebula